VOLUME 15 | NUMBER 4 | APRIL 2012 nature neurOSCIenCe a r t I C l e S The brain represents only 2% of the total body weight in mammals, but it consumes up to 20% of the body's resting energy production 1,2 . Ensuring and regulating cellular energy supplies, mitochondria are key elements of eukaryotic cell functions 1,3 that are crucial for the regulation of brain functions 1, 4 . The involvement of neuronal energetics in brain physiology and pathology is the focus of intensive research 1, 4, 5 , but the molecular mechanisms linking mitochondrial activity to brain functions are still poorly documented. G protein-coupled receptors (GPCRs) represent one of the largest protein families controlling neuronal activity. The presence of GPCRs on neuronal mitochondria and their potential ability to modulate neuronal energetics and function is still a matter of speculation 6 . However, there is now consistent evidence that mitochondria contain G proteins 7, 8 . Moreover, several reports have shown the intramitochondrial localization of potential downstream effectors of G protein signaling, such as soluble adenylyl cyclase 9 , phosphodiesterase 10,11 and protein kinase A (PKA) 12 . Thus, cAMP can be produced in mitochondria, leading to activation of PKA and phosphorylation of mitochondrial proteins, eventually regulating mitochondrial respiration and energy production 10, 11, 13, 14 . However, the upstream mechanisms regulating the intramitochondrial cAMP-PKA signaling cascade in neurons, and the mechanisms coupling mitochondrial activity and neuronal physiology, remain poorly understood 1,4 . CB 1 receptors are GPCRs highly enriched in neuronal plasma membranes, where they tightly control neuronal activity, metabolism and functions [15] [16] [17] . Early studies suggested that the Cannabis sativa (marijuana)-derivative cannabinoid ∆ 9 -tetrahydrocannabinol (THC) could affect mitochondrial functions 18 . However, with the identification of cannabinoid receptors as typical plasma membrane GPCRs 15,19 , mitochondrial effects of lipophilic cannabinoids on neurons were ascribed to nonspecific alterations of membrane properties 20 . Recent evidence points also to the ability of CB 1 receptor signaling to regulate mitochondrial biogenesis in peripheral non-neural tissues 21, 22 . The lipophilic nature of most cannabinoids 15 implies that receptor-ligand interactions might occur not only at plasma membranes, but also inside cells. Indeed, different intracellular compartments contribute to the regulation of endocannabinoid metabolism 23, 24 , and CB 1 receptors have been shown to functionally signal in lysosomal or endosomal intracellular membranes 25 .
CB 1 receptors are GPCRs highly enriched in neuronal plasma membranes, where they tightly control neuronal activity, metabolism and functions [15] [16] [17] . Early studies suggested that the Cannabis sativa (marijuana)-derivative cannabinoid ∆ 9 -tetrahydrocannabinol (THC) could affect mitochondrial functions 18 . However, with the identification of cannabinoid receptors as typical plasma membrane GPCRs 15, 19 , mitochondrial effects of lipophilic cannabinoids on neurons were ascribed to nonspecific alterations of membrane properties 20 . Recent evidence points also to the ability of CB 1 receptor signaling to regulate mitochondrial biogenesis in peripheral non-neural tissues 21, 22 . The lipophilic nature of most cannabinoids 15 implies that receptor-ligand interactions might occur not only at plasma membranes, but also inside cells. Indeed, different intracellular compartments contribute to the regulation of endocannabinoid metabolism 23, 24 , and CB 1 receptors have been shown to functionally signal in lysosomal or endosomal intracellular membranes 25 .
The present study stemmed from the neuroanatomical observation that CB 1 receptor immunogold particles are often detected on neuronal mitochondria in electron microscopy experiments, but they are generally considered nonspecific background labeling. This observation prompted us to investigate the specificity of this signal by using mutant mice constitutively lacking the CB 1 receptor 26 . The results showed that CB 1 receptors are present on neuronal mitochondrial a r t I C l e S membranes, and their direct activation regulates mitochondrial energetics. Furthermore, stimulation of intracellular CB 1 receptors and inhibition of presynaptic mitochondrial activity participate in endocannabinoid-dependent regulation of short-term synaptic plasticity in the hippocampus, providing a possible link between neuronal energy metabolism and specific neuronal functions. RESULTS CB 1 receptor protein is localized on neuronal mitochondria CB 1 receptor immunoreactivity was detected by immunogold electron microscopy on mitochondrial membranes of CA1 hippocampal neurons of wild-type mice (mtCB 1 ; Fig. 1a and Supplementary  Fig. 1a ), but not Cnr1 −/− (here called CB 1 −/− ) littermates ( Fig. 1b  and Supplementary Fig. 1b) . Approximately 30% of wild-type CA1 mitochondria displayed CB 1 immunolabeling, whereas only 2.9% ± 0.7% of CA1 mitochondria in CB 1 −/− mice showed nonspecific labeling (Fig. 1c) . MtCB 1 receptors were comparably distributed between axon terminals and somato-dendritic compartments in wild-type mice ( Supplementary Fig. 2a ). The density of mtCB 1 immunogold labeling was 18.3 ± 2.0 particles per µm 2 of mitochondria in wild type and dropped to 0.4 ± 0.1 particles per µm 2 in CB 1 −/− mice ( Fig. 1d) . Further quantifications revealed that 15.5% ± 4.2% of CA1 neuronal total CB 1 protein was localized to mitochondria. Western immunoblotting confirmed the specific presence of CB 1 immunoreactivity in purified wild-type brain mitochondria ( Fig. 1e and Supplementary  Fig. 3 ). Semiquantification of immunogold images revealed that approximately 95% of mtCB 1 was localized to the outer membrane of mitochondria (Fig. 1f) . This was confirmed by Western immunoblotting of purified mitochondria treated with trypsin with or without digitonin presolubilization, suggesting that the N-terminal portion of mtCB 1 is exposed to the cytosol, whereas the C terminus is likely located in the mitochondrial intermembrane space ( Fig. 1g and Supplementary Fig. 4 ). Thus, a substantial portion of CB 1 receptor protein is present at the surface of neuronal mitochondria. CB 1 receptors are expressed in different neuronal populations, where they negatively regulate excitability and neurotransmission [15] [16] [17] . These include inhibitory neurons containing GABA and excitatory glutamatergic neurons 24 , where activation of CB 1 receptors differentially affects brain functions and behavior 16, 17, 27, 28 . We analyzed the anatomical distribution of mtCB 1 receptors in the hippocampus of conditional mutant mice lacking CB 1 either in cortical glutamatergic (Glu-CB 1 −/− ) or in GABAergic (GABA-CB 1 −/− ) neurons, respectively 27, 28 . MtCB 1 was still present in CA1 hippocampal neurons of both mutant strains (Fig. 2a,b and Supplementary Fig. 1c,d) , with similar reductions in the percentage of labeled mitochondria relative to that in wild-type mice (Fig. 2c) . In contrast, the density of mtCB 1 was reduced by 50.4% in GABA-CB 1 −/− , but not in Glu-CB 1 −/− , mutants (Fig. 2d) . No difference between these two genotypes was observed concerning the proportion of mtCB 1 versus total CB 1 expression (Fig. 2e) . As expected, most mtCB 1 was detected in terminals bearing asymmetric synapses (presumably excitatory) in GABA-CB 1 −/− mice, whereas it was almost exclusively present on mitochondria of presumably inhibitory symmetric synapses in Glu-CB 1 −/− mice ( Supplementary Fig. 2b ). Thus, both neuronal populations contain mtCB 1 receptors, which are, however, more densely expressed in hippocampal GABAergic neurons than in glutamatergic ones.
MtCB 1 directly regulates brain mitochondrial activity
The acute administration of THC to C57BL6/N mice (intraperitoneally, 5 mg per kilogram body weight) reduced mitochondrial Resistance of mtCB 1 C-terminal domain to trypsin digestion but not to mild membrane permeabilization by digitonin (digit) indicates that the receptor is localized on the outer membrane with the C-terminal portion of the protein facing the mitochondrial intermembrane space. Full-length blots are shown in Supplementary Figure 4 . Den, dendrites; ter, terminals; m, mitochondria; OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; mat., matrix; Tom20, translocase of outer mitochondrial membranes 20 kDa; CIII, core 2 protein of mitochondrial complex III. Values, mean ± s.e.m. ***P < 0.001 as compared to WT. Fig. 3a ) and treated in vitro with the synthetic CB 1 agonist WIN55,212-2 (WIN). The drug dose-dependently decreased oxygen consumption in brain mitochondria from wild-type, but not CB 1 −/− , mice (Fig. 3a) . WIN specifically decreased mitochondrial complex I activity (Fig. 3b) and cAMP content (Fig. 3c) . Hippocampal neuronal mitochondria contained the A-kinase anchor protein 121 (AKAP121; Supplementary Fig. 1e ), confirming that PKA activity occurs in these organelles 12 . WIN decreased mitochondrial PKA activity in an mtCB 1 -dependent manner (Fig. 3d) . To establish whether hippocampal CB 1 expression is sufficient for the mitochondrial effects of WIN, we injected the hippocampi of CB 1 −/− mice with neurotropic adenoassociated viruses (AAV) expressing either a control protein (green fluorescent protein, AAV-GFP) or CB 1 (AAV-CB 1 ) 31 . The effect of WIN on complex I activity of purified hippocampal mitochondria was fully rescued by in vivo viral re-expression of the CB 1 receptor in CB 1 −/− hippocampal mitochondria (Fig. 3e) . To investigate whether mtCB 1 is responsive to natural plant-derived cannabinoids, we measured the effects of THC on respiration, cAMP levels and PKA activity in neuronal mitochondria from wild-type and CB 1 −/− littermates. THC induced effects similar to those of WIN ( Fig. 4a-c) , indicating that the functions of mtCB 1 are not dependent on the type of ligand.
Brain mitochondria have substantial levels of endocannabinoid degrading activity (Supplementary Table 1 ). To test whether endocannabinoids regulate mitochondrial activity in situ, we treated purified brain mitochondria with JZL195 (JZL), a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the two main endocannabinoid degrading enzymes 15, 32 , and measured mitochondrial endocannabinoid levels and respiration. The endocannabinoid anandamide was detected in purified neuronal mitochondria, but its levels were below the limits of reliable quantification (data not shown). However, JZL dose-dependently increased mitochondrial 2-arachidonoylglycerol ( Fig. 4d) and reduced respiration in brain mitochondria from wild-type, but not CB 1 −/− , mice (Fig. 4e) . Notably, a highly significant inverse correlation was observed between 2-arachidonoylglycerol levels and mitochondrial respiration in wild-type brain mitochondria (r = 0.82, P < 0.0001; Fig. 4f) .
Together, these data show that (i) mtCB 1 signaling directly affects mitochondrial cAMP accumulation, PKA activity, complex I activity and respiration in the brain, and (ii) mitochondria are equipped with endocannabinoids able to activate mtCB 1 in situ. −/− hippocampi locally injected with AAV-GFP, and from CB 1 −/− hippocampi locally injected with AAV-CB 1 (n = 6 per group). Values, mean ± s.e.m. *P < 0.05, **P < 0.01; ***P < 0.001 as compared to control (vehicle or time 0); # P < 0.05, ## P < 0.01 as compared to WT. Dashed horizontal lines, values for vehicle-treated controls. a r t I C l e S Intracellular CB 1 receptors participate in DSI If mtCB 1 can control brain mitochondrial activity, are mitochondria involved in endocannabinoid-dependent neuronal functions? Retrograde control of hippocampal GABAergic transmission is an important endocannabinoid-dependent form of synaptic plasticity [15] [16] [17] . Depolarization of CA1 postsynaptic pyramidal neurons mobilizes endocannabinoids, which retrogradely activate presynaptic CB 1 receptors, transiently decreasing GABAergic inhibitory neurotransmission in a process known as depolarization-induced suppression of inhibition (DSI) [15] [16] [17] . DSI is blocked by CB 1 receptor antagonists and is occluded by CB 1 receptor agonists, which prevent the binding and the action of endogenously mobilized endocannabinoids 16 . If intracellular mtCB 1 receptors participate in the expression of DSI, cell-impermeant CB 1 receptor antagonists and agonists should not be able to fully block and occlude DSI, respectively. The peptide CB 1 receptor antagonist hemopressin 25, 33, 34 provided a first tool to test this hypothesis. As a peptide, hemopressin should not be able to penetrate plasma membranes 25 . This was confirmed both by measurements of intracellular fluorescence of cells treated with a fluorescent derivative of hemopressin (Supplementary Fig. 5a-c) and by spectrometric analysis of extracts from hippocampal slices incubated with hemopressin and the lipophilic CB 1 antagonist AM251 ( Supplementary  Fig. 5d-f) . Thus, hemopressin can be used as a cell-impermeant CB 1 receptor antagonist.
To investigate the occluding effects of cell-impermeant CB 1 receptor agonists on DSI and to discriminate the relative influence of plasma membrane and intracellular CB 1 receptors on cellular respiration, we synthesized a biotinylated version of the lipophilic CB 1 receptor agonist HU210 (HU210-biotin, hereafter HU-biot). The presence of the hydrophilic biotin bulk should impede the cell penetration of this compound, and the presence of a spacer between the HU210 scaffold and the biotin moiety should preserve the affinity for CB 1 receptors. Radioligand competition experiments revealed that HUbiot displayed a comparable affinity for recombinant CB 1 receptors to that of HU210 (HU210, K i = 0.2 ± 0.07 nM; HU-biot, K i = 1.5 ± 0.4 nM). To characterize the ability of HU210 and HU-biot to penetrate plasma membranes and stimulate mtCB 1 receptors, we transfected primary mouse fibroblast cultures derived from CB 1 −/− pups with a plasmid expressing the CB 1 receptor (creating MF-CB 1 cells). Neither HU210 nor HU-biot had any effect on cellular respiration of mock-transfected CB 1 −/− mouse fibroblasts (Fig. 5a) . Conversely, only HU210, but not HU-biot, decreased cellular respiration in MF-CB 1 cells (Fig. 5b) , suggesting that cell penetration is a necessary step for this effect. Accordingly, HU-biot became as efficient as HU210 in depressing cell respiration in permeabilized MF-CB 1 cells (Fig. 5c) , indicating that both drugs activate mtCB 1 receptors, but the difference relies on their cell permeance. Notably, hemopressin was not able to alter the effect of HU210 on intact MF-CB 1 cells (Fig. 5b) , but it fully blocked this effect in permeabilized cells (Fig. 5c) . These data indicate that (i) the lipophilic CB 1 agonist HU210 can penetrate cells and alter cellular respiration, (ii) HU-biot and hemopressin do not penetrate intact cells and do not alter cellular respiration, and, notably, (iii) only the activation of intracellular CB 1 receptors affects mitochondrial respiration of living cells.
We next analyzed the impact of the cell-permeant CB 1 antagonist AM251 and agonist HU210 on inhibitory synaptic transmission and DSI, and compared their effects to those of the cell-impermeant antagonist Values, mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to vehicle control; # P < 0.05, ## P < 0.01, ### P < 0.001 as compared to WT. Dashed lines, vehicle values. VOLUME 15 | NUMBER 4 | APRIL 2012 nature neurOSCIenCe a r t I C l e S hemopressin and agonist HU-biot, respectively. As expected 16 , a 'strong' DSI induced by a 5-s depolarization of CA1 pyramidal neurons was fully blocked by AM251 (Fig. 6a) . The application of hemopressin at a high dose (10 µM) did not alter evoked inhibitory postsynaptic currents (eIPSCs) when applied to hippocampal slices ( Supplementary Fig. 6a,b) . However, the peptide antagonist only partially and reversibly reduced DSI amplitude ( Fig. 6a and  Supplementary Fig. 6c,d ). High concentrations of HU210 and HU-biot (500 nM) displayed a very similar ability to reduce eIPSCs (Fig. 6b) , independently of the frequency of stimulation of afferent fibers (Supplementary Fig. 6a,b) . Notably, the extracellular antagonist hemopressin fully blocked the depression of eIPSCs by both HU210 and HU-biot (Supplementary Fig. 6a,b) , suggesting that intracellular CB 1 receptor signaling is not required for this pharmacological cannabinoid effect and that the biotin moiety does not alter the effect of HU210 on hippocampal GABAergic transmission. The maximal eIPSCs-depressing effect of both HU210 and HU-biot was observed after 25-30 min of incubation ( Fig. 6b and Supplementary Fig. 6a) . As expected, a 30-min incubation with HU210 fully occluded DSI induction in hippocampal slices ( Fig. 6c and Supplementary Fig. 6d ). In contrast, HU-biot only partially occluded DSI at concentrations of both 500 nM and 5 µM (Fig. 6c and Supplementary Fig. 6d ). Thus, cell penetration of CB 1 antagonists and agonists is necessary for the respective full blockade and occlusion of DSI induced by 5-s depolarization of postsynaptic pyramidal neurons.
Inhibition of mitochondrial activity contributes to DSI
Rotenone is a well known specific and potent mitochondrial complex I inhibitor. The application of rotenone to hippocampal slices (2.5 µM) had no effect on strong DSI induced by a long depolarization period (5 s; Fig. 7a) . However, if a weaker DSI was induced by a 1-s depolarization step, rotenone reliably enhanced DSI amplitude (Fig. 7b) . Rotenone was unable to affect eIPSCs in the absence of depolarization (Supplementary Fig. 7a) , to induce DSI in slices from CB 1 −/− mice in the presence of the depolarization ( Supplementary  Fig. 7b) , to alter the inhibitory effects of HU-biot on eIPSCs (Supplementary Fig. 7c ), or to modify the levels of mitochondrial endocannabinoids (Supplementary Fig. 7d ). These results indicate that the effect of rotenone on DSI was not due to a direct alteration of inhibitory neurotransmission, that it was dependent on CB 1 receptors, and that it was not due to increase in local endocannabinoid levels. DSI is mediated by presynaptic CB 1 receptors 16 . Rotenone did not (1 and 2, traces before and after depolarization, respectively); bottom, summary of results. Values, mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.0001 as compared to control DSI. ## P < 0.01; ### P < 0.001. a r t I C l e S produce any effect when infused postsynaptically (Fig. 7c) , suggesting the involvement of presynaptic mitochondria in the expression of strong DSI. Consistent with these data, hemopressin was able to fully abolish a weak DSI induced by a 1-s depolarization (Fig. 7d) , further confirming that intracellular CB 1 receptors contribute to strong, but not weak, forms of DSI.
DISCUSSION
The present results show that the CB 1 GPCR is present in a portion (approximately 30% in the hippocampus) of brain neuronal mitochondria, where it directly regulates mitochondrial respiration. This function may be exerted through the modulation of complex I activity, by regulating cAMP levels and PKA activity, which have been recently proposed to occur in mitochondria and to modulate the organelle's respiration and energy production 7, 8, 11, 13, 14, 30 . Intracellular CB 1 receptors are involved in DSI, an endocannabinoiddependent form of short-term plasticity of inhibitory neurotransmission in the hippocampus, and this function is mimicked by direct inhibition of complex I activity. Thus, these data establish the existence of mtCB 1 receptors and their role in the regulation of neuronal bioenergetics, which might be involved in endocannabinoid-dependent synaptic plasticity. The hypothesis that GPCRs may directly regulate mitochondrial activity has been recently proposed 6, 30 . The open source program MitoProt II (ref. 35 ) predicted the CB 1 receptor protein to bear a 39.3% probability of mitochondrial localization (Supplementary Table 2 ). This theoretical value is much higher than that of many GPCRs and is comparable to the values of several known or recently identified mitochondrial proteins (Supplementary Table 2) . Our experimental data demonstrate that the metabotropic CB 1 receptor is present on mitochondrial membranes of neurons, where it acutely regulates energy metabolism and likely contributes to the expression of DSI.
The proportion of CB 1 receptors located on the mitochondrial membrane (approximately 15% of total cell CB 1 receptors) might seem low. However, this expression accounts for up to 30% of mtCB 1 -dependent reduction of respiration in purified brain mitochondria. Notably, approximately 30% of neuronal mitochondria do contain CB 1 receptors, suggesting a strong impact of cannabinoid signaling on the subset of organelles expressing mtCB 1 . Moreover, a low abundance of CB 1 receptors can bear crucial functional significance in specific locations. Although a minimal amount (less than 10%) of total cortical CB 1 receptor proteins are expressed in glutamatergic neurons 24, 27 , many of the functions of the endocannabinoid system are exerted by this limited percentage of receptors. For instance, protection against excitotoxic seizures or the orexigenic properties of endocannabinoid signaling are mainly exerted by glutamatergic-neuron CB 1 receptors 27, 28 . Therefore, the 15% of hippocampal CB 1 protein located on mitochondrial membranes cannot be considered a negligible amount from a functional point of view.
Neuronal bioenergetics is emerging as a key player in brain functions 1,2,4,5 . This holds true for neurodegenerative disorders, in which mitochondrial alterations are thought to be of etiopathological relevance 4 . However, mitochondria also influence the normal functioning of the brain, regulating synaptic plasticity and possibly behavior 1,2,4,5 . The identification and functional characterization of brain mtCB 1 receptors provides a new mechanism of modulation of neuronal activity, which might have key roles in both physiological and pathological brain processes.
CB 1 -dependent forms of synaptic plasticity such as DSI are likely to underlie many functions of endocannabinoid signaling in the brain [15] [16] [17] . Neurotransmitter release is a very energy-demanding process 5 , and mitochondria can modulate its efficiency by different means 4 . The membrane-impermeant CB 1 receptor agonist HU-biot and the antagonist hemopressin only partially occluded and blocked DSI, respectively. In addition, inhibition of presynaptic mitochondrial activity by rotenone potentiated this form of synaptic plasticity, suggesting the involvement of mitochondrial activity in DSI. The latter effect could also be due to indirect effects of rotenone, which might potentiate endocannabinoid signaling by stimulation of neurotransmitter (for example, glutamate) 36 release, which can in turn increase endocannabinoid mobilization 16 . This is, however, unlikely because the application of rotenone postsynaptically or in the absence of postsynaptic depolarization did not alter inhibitory transmission. If rotenone were stimulating indirectly endocannabinoid mobilization per se, its application to slices should result into alterations of eIPSCs. Indeed, previous studies have shown that much higher concentrations of rotenone and much longer application periods are needed to alter synaptic transmission in the hippocampus 37 . Reduction of eIPSCs by exogenous application of cannabinoids does not seem to involve intracellular CB 1 . Conversely, our data clearly show that intracellular CB 1 receptors (likely mtCB 1 ) participate in strong DSI. These apparently contradictory results suggest a mechanistic difference between the decrease of eIPSCs induced by exogenously applied cannabinoids or endogenously mobilized endocannabinoids. As yet, the mechanistic bases of this paradoxical difference are unknown, but they might rely on temporal and/or spatial aspects 17 . DSI is short-lasting (a few tens of seconds), likely due to efficient endogenous degradation of endocannabinoids 15, 17 . Conversely, drug applications (especially of lipophilic cannabinoids) are generally long-lasting, their duration depending only on pharmacokinetics properties of the drug, and might induce extra effects (for example, tolerance) 29 . From the spatial point of view, the mobilization of endocannabinoids by depolarization and/or synaptic stimulation might be limited to specific cellular subdomains. Conversely, exogenous cannabinoids might display preference for other subdomains, thereby triggering different mechanisms. Finally, depolarization steps able to endogenously mobilize endocannabinoids might trigger other, so far unknown cellular events to favor additional means of endocannabinoid signaling, which would otherwise remain silent.
Taken together, our results show that intracellular CB 1 receptors participate in DSI and suggest that mtCB 1 might be the mediator of this intracellular endocannabinoid signaling. Endocannabinoids acting at presynaptic mtCB 1 receptors might contribute to DSI by temporarily decreasing mitochondrial respiration and altering the energy supply in the form of ATP needed for the ongoing release of neurotransmitters 4, 5 . Moreover, mitochondria regulate intracellular calcium levels and redox potential, which can also modulate neuronal activity and neurotransmitter release 4 . Rapid trafficking of mitochondria has also been recently proposed to modulate synaptic plasticity 1 , raising the possibility that mtCB 1 might interfere with these processes. Thus, mtCB 1 receptors might contribute to DSI and possibly to other forms of synaptic regulation and plasticity by different means.
The discovery that intracellular CB 1 receptor signaling and mitochondrial regulation are involved in DSI further extends the range of mechanisms through which endocannabinoid signaling influences brain functions and will possibly add new pharmacological targets for the therapeutic exploitation of the endocannabinoid system. The demonstration that CB 1 receptors are functionally expressed on neuronal mitochondria will pave the way for new studies investigating in deeper detail the relationship between GPCR signaling in the brain and cellular energy regulation, with unforeseeable effect on the development of new theoretical frameworks to better understand brain functioning in health and disease. VOLUME 15 | NUMBER 4 | APRIL 2012 nature neurOSCIenCe a r t I C l e S METHODS Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
previously 44 . The amounts of anandamide and 2-AG were determined using a calibration curve and were expressed as nmol or pmol per mg of protein, respectively. Anandamide was detected in the samples, but at levels below the limit of reliable quantification. Therefore, only data relating to 2-AG are presented. Viral rescue of cB1 expression in the hippocampus. Cloning of hemagglutinin (HA)-tagged rat CB 1 receptor (AAV-CB 1 ) or green fluorescent protein (AAV-GFP) into an AAV expression cassette, packaging of AAV1/2 chimeric vectors and determination of genomic titers were as described 31, 45 . One µl of either AAV-GFP or AAV-CB1 (6 × 10 11 viral genomes ml −1 ) was injected bilaterally at 150 nl min −1 into the dorsal and ventral hippocampus (−2.0 mm AP, ± 2.0 mm ML, −2.0 mm DV; −3.5 mm AP, ± 3.4 mm ML, −3.0 mm DV from bregma, respectively). Animals were used for experiments five weeks after viral injection 31 . Fig. 4a-c) in incubation buffer plus 0.5% BSA, detached with trypsin, and fixed with 0.01% formaldehyde (10 min). Fluorescence was measured by flow cytometry (FACScan, Cytek). Some cells were permeabilized with 0.5% NP-40 in PBS before incubation. Images were acquired with a Nikon TS100 fluorescence microscope and video camera using the NIS Elements D software. measurement of hemopressin and Am251 by liquid chromatography/mass spectrography. Slices previously incubated with 10 µM hemopressin or AM251 (same conditions as in electrophysiology experiments) were rinsed with water, centrifuged, Dounce-homogenized in chloroform:methanol:water (2:1:1; 2 ml), and the organic and aqueous layers separated by centrifugation. For hemopressin, the aqueous phase was dried under a stream of argon and reconstituted in 100 µL H 2 O, and 60 µL were analyzed by LC/MS. For AM251, the organic phase was dried under a stream of argon and reconstituted in 100 µL of acetonitrile, and 50 µL were analyzed by LC/MS. LC/MS was carried out in an Agilent 1200LC-MSD VL instrument with an Eclipse XDB-C18 column coupled to an ESI source in SIM mode. The mobile phases were A (95:5 water:methanol) and B (95:5 methanol:water) with 0.1% ammonium hydroxide and 0.1% formic acid. Fractions were quantified by measuring the area under the peak and compared to corresponding standards. electrophysiology. Preparation of hippocampal slices and recording of eIPSCs were as previously described 28, 46 . After reaching stable baseline (~10 min after reaching whole-cell configuration for infusion of intracellular solution), IPSCs were evoked using a patch pipette filled with a HEPES-based extracellular solution positioned in the stratum radiatum, 100 µm from the CA1 pyramidal cell layer. DSI expression was checked before starting each experiment with a 5-s depolarization protocol 46 . Control experiments showed that this 'initial' DSI had no effect on following recorded DSI (not shown).
To determine the effects of HU210 (500nM), HU-biot (500nM) and rotenone (2.5 µM) on basal inhibitory synaptic transmission, IPSCs were evoked every 10-15 s. To determine the effects of HU210, HU-biot, hemopressin (10 µM) and rotenone on basal inhibitory synaptic transmission using the same conditions of afferent stimulation as during DSI protocols (see below), IPSCs were evoked every 3 s and a stable baseline was recorded (time 0). Then, drugs (or vehicle) were applied and patched cells were left undisturbed. The same stimulation protocol was then applied every 10 min after drug applications up to 30 min.
For DSI, IPSCs were evoked every 3 s, and DSI was induced by a 1-s or a 5-s voltage step from −70 to 0 mV applied to the postsynaptic pyramidal neuron and calculated as described 46 .
Two different treatment schemes were used to evaluate the effect of the different drugs on DSI. In some experiments (Fig. 6a,c and 7d) , slices were first incubated with drugs (or vehicle) for 30 min. A CA1 pyramidal cell was then patched and, after a stable baseline was obtained, a DSI protocol was applied. In other experiments (Fig. 7a-c and Supplementary Figs. 6a-c and 7b,c) , a pairwise schedule was used: CA1 pyramidal neurons were patched and, after we obtained a stable baseline, a DSI protocol was applied. Then, drugs were applied and a new DSI protocol was applied after 15 min of baseline recording. The effect of postsynaptic rotenone on DSI was studied by adding the drug (2.5 µM) to the intracellular solution in the patch pipette.
Statistical analyses. All graphs and statistical analyses were performed using GraphPad software (version 5.0). Results were expressed as means of independent data points ± s.e.m. Data were analyzed using a paired or unpaired Student's t-test, one-way ANOVA (followed by Newman-Keuls post hoc test), or two-way ANOVA (followed by Bonferroni's post hoc test), as appropriate.
